OTHER HIGHLIGHTS
The Immunotronics™ platform is currently undergoing several different pre-clinical trials and testing regarding inflammation caused by an extremely diverse set of diseases.
ENDV announced this month that it will be commencing a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in preventing and reversing inflammation and fibrosis in kidney disease. The study is the first of several currently planned studies targeting inflammatory pathologies of renal origin, including ischemia/reperfusion injury, acute kidney injury and diabetic nephropathy.
In May ENDV discussed its pre-clinical trial to assess the effects of their Immunotronics™ platform in preventing and reversing inflammation in Non-Alcoholic Steatohepatitis (NASH). The study is the first of several currently planned studies targeting inflammatory pathologies of hepatic origin.
In regard to ENDV’s work in the reversing inflammation for NASH patients, highlighting the diverse use for their number one platform, their CEO stated “We are delighted starting our liver disease pipeline targeting large and unmet clinical needs, particularly in fatty liver disease.”
A pre-clinical study evaluating the effect of the Company’s non-invasive electroceutical technology on limb function, ischemia damage and blood flow, including the formation of new blood vessels (angiogenesis) is currently undergoing. The study is part of the Company’s strategy to develop a pipeline of non-invasive electroceutical treatments for vascular diseases, ischemia/reperfusion injuries, and ischemia wounds.
Endonovo is requesting the United States Food and Drug Administration (FDA) grant an orphan drug designation to its next-generation, off-the-shelf treatment for Graft-Versus-Host Disease (GVHD) using Cytotronics™ expanded and ex vivo enhanced stem cells from the human umbilical cord.
Time-Varying Electromagnetic Field (TVEMF) technology is fundamentally different from other magnetic pulse devices. TVEMF is based on the physics of electricity and magnetism as well as the physiology of cells and tissues. Endonovo’s TVEMF device produces a patented square waveform, which was proven the most effective waveform to increase cell growth and the production of over 200 growth factors and cytokines.
The basis for Endonovo’s (OTC: ENDV) Time-Varying Electromagnetic Field (TVEMF) technology was created at NASA in conjunction with the development of cell therapies to treat injuries and diseases that astronauts might encounter during long-term manned missions in outer space.
The original concept of TVEMF was developed when NASA realized that cellular growth increased as the space shuttle crossed the earth’s magnetic poles. It took over eight years to define and develop a device that produced the same effect. This magnetic field device (TVEMF) was originally designed to enhance cellular expansion (growth) in NASA’s rotating wall bioreactor. After numerous experimental studies, the results were so significant with the bioreactor that a prototype was designed for use directly on the human body.
Cytotronics™ Platform Allows for the Large-Scale Expansion and Enhancement of Immuno-Regulatory Stem Cells With Enhanced Biological and Therapeutic Properties.
Ex-Vivo-Modulation – Endonovo Therapeutics (OTC: ENDV) Files Patent Application on Cell Therapy Created Using Its Proprietary Cell-Enhancing Cytotronics Platform
Therapeutic Represents the First Product to Be Created Using the Company’s Cytotronic™ Platform to Expand and Enhance the Therapeutic Properties of Stem Cells.
The prospect of increasing the availability and safety of cord blood transplants has attracted the attention of large pharmaceutical companies, such as Swiss drug maker Novartis, which recently announced another $15 million investment in Israeli stem cell company, Gamida Cell.
In April, Endonovo provided a corporate update in which it indicated the buyback of $154,303 in convertible notes, in an attempt to preserve shareholder value as well as position the company to attract institutional investors.
On March 30, Endonovo announced that it has received a Notice of Allowance from the US Patent and Trademark Office for a patent application entitled “Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells.” The patent application covers the production of biological molecules in adult stem cells, which can be used to produce human proteins. The Notice of Allowance indicates that the company could receive a US patent in the near future. Going by CEO Alan Collier’s comments, Endonovo may license this technology or partner with a larger pharmaceutical company to develop it.
In February, Endonovo filed the paperwork to obtain an orphan drug designation for Cytotronics. The orphan drug status, granted by the FDA, would entitle the company to a 7-year period of marketing exclusivity in the US for the treatment of Graft-Versus-Host Disease (GVHD).
http://biotechmarketreport.com/
Report TOS
The Immunotronics™ platform is currently undergoing several different pre-clinical trials and testing regarding inflammation caused by an extremely diverse set of diseases.
ENDV announced this month that it will be commencing a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in preventing and reversing inflammation and fibrosis in kidney disease. The study is the first of several currently planned studies targeting inflammatory pathologies of renal origin, including ischemia/reperfusion injury, acute kidney injury and diabetic nephropathy.
In May ENDV discussed its pre-clinical trial to assess the effects of their Immunotronics™ platform in preventing and reversing inflammation in Non-Alcoholic Steatohepatitis (NASH). The study is the first of several currently planned studies targeting inflammatory pathologies of hepatic origin.
In regard to ENDV’s work in the reversing inflammation for NASH patients, highlighting the diverse use for their number one platform, their CEO stated “We are delighted starting our liver disease pipeline targeting large and unmet clinical needs, particularly in fatty liver disease.”
A pre-clinical study evaluating the effect of the Company’s non-invasive electroceutical technology on limb function, ischemia damage and blood flow, including the formation of new blood vessels (angiogenesis) is currently undergoing. The study is part of the Company’s strategy to develop a pipeline of non-invasive electroceutical treatments for vascular diseases, ischemia/reperfusion injuries, and ischemia wounds.
Endonovo is requesting the United States Food and Drug Administration (FDA) grant an orphan drug designation to its next-generation, off-the-shelf treatment for Graft-Versus-Host Disease (GVHD) using Cytotronics™ expanded and ex vivo enhanced stem cells from the human umbilical cord.
Time-Varying Electromagnetic Field (TVEMF) technology is fundamentally different from other magnetic pulse devices. TVEMF is based on the physics of electricity and magnetism as well as the physiology of cells and tissues. Endonovo’s TVEMF device produces a patented square waveform, which was proven the most effective waveform to increase cell growth and the production of over 200 growth factors and cytokines.
The basis for Endonovo’s (OTC: ENDV) Time-Varying Electromagnetic Field (TVEMF) technology was created at NASA in conjunction with the development of cell therapies to treat injuries and diseases that astronauts might encounter during long-term manned missions in outer space.
The original concept of TVEMF was developed when NASA realized that cellular growth increased as the space shuttle crossed the earth’s magnetic poles. It took over eight years to define and develop a device that produced the same effect. This magnetic field device (TVEMF) was originally designed to enhance cellular expansion (growth) in NASA’s rotating wall bioreactor. After numerous experimental studies, the results were so significant with the bioreactor that a prototype was designed for use directly on the human body.
Cytotronics™ Platform Allows for the Large-Scale Expansion and Enhancement of Immuno-Regulatory Stem Cells With Enhanced Biological and Therapeutic Properties.
Ex-Vivo-Modulation – Endonovo Therapeutics (OTC: ENDV) Files Patent Application on Cell Therapy Created Using Its Proprietary Cell-Enhancing Cytotronics Platform
Therapeutic Represents the First Product to Be Created Using the Company’s Cytotronic™ Platform to Expand and Enhance the Therapeutic Properties of Stem Cells.
The prospect of increasing the availability and safety of cord blood transplants has attracted the attention of large pharmaceutical companies, such as Swiss drug maker Novartis, which recently announced another $15 million investment in Israeli stem cell company, Gamida Cell.
In April, Endonovo provided a corporate update in which it indicated the buyback of $154,303 in convertible notes, in an attempt to preserve shareholder value as well as position the company to attract institutional investors.
On March 30, Endonovo announced that it has received a Notice of Allowance from the US Patent and Trademark Office for a patent application entitled “Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells.” The patent application covers the production of biological molecules in adult stem cells, which can be used to produce human proteins. The Notice of Allowance indicates that the company could receive a US patent in the near future. Going by CEO Alan Collier’s comments, Endonovo may license this technology or partner with a larger pharmaceutical company to develop it.
In February, Endonovo filed the paperwork to obtain an orphan drug designation for Cytotronics. The orphan drug status, granted by the FDA, would entitle the company to a 7-year period of marketing exclusivity in the US for the treatment of Graft-Versus-Host Disease (GVHD).
http://biotechmarketreport.com/
Report TOS
